| Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update |
sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 |
globenewswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism |
Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by HI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational therapy, ersodetug, for the treatment of hypoglycemia caused by tumor HI. |
globenewswire.com |
2025-05-05 12:00:00 |
Czytaj oryginał (ang.) |
| Rezolute to Participate in Upcoming Investor Conferences |
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences: |
globenewswire.com |
2025-05-01 12:00:00 |
Czytaj oryginał (ang.) |
| Rezolute: RZ402 Could Be A Surprise Candidate In The Making |
Topline results from phase 3 sunRIZE study, using ersodetug for the treatment of patients with congenital hyperinsulinism, expected in December 2025. Proof-of-concept was established in a phase 2 study using the oral small molecule plasma kallikrein inhibitor RZ402 for the treatment of patients with diabetic macular edema. The global diabetic macular edema market size is projected to reach $7.5 billion by 2034. |
seekingalpha.com |
2025-05-01 07:57:55 |
Czytaj oryginał (ang.) |
| Rezolute, Inc. Announces Closing of Underwritten Offering |
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of its previously announced underwritten offering (the “Offering”) of an aggregate of 24,940,769 shares of its common stock at an offering price of $3.25 per share, which includes 4,153,846 shares of common stock pursuant to the exercise in full of the underwriters' option to purchase additional shares of common stock and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 6,905,385 shares of common stock at an offering price of $3.2490 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. |
globenewswire.com |
2025-04-25 20:30:00 |
Czytaj oryginał (ang.) |
| Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December |
Rezolute, Inc. RZLT on Wednesday announced the Independent Data Monitoring Committee's (DMC) recommendation to continue the Phase 3 sunRIZE study as planned in patients with congenital hyperinsulinism (HI) without increasing the study sample size. |
benzinga.com |
2025-04-23 19:50:43 |
Czytaj oryginał (ang.) |
| Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants |
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of an underwritten offering, priced at-the-market under Nasdaq rules, of an aggregate of 20,786,923 shares of its common stock at an offering price of $3.25 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 6,905,385 shares of common stock at an offering price of $3.2490 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Gross proceeds from the underwritten offering before deducting underwriting discounts and commissions and other offering expenses are expected to be approximately $90 million. Rezolute has also granted the underwriters a 30-day option to purchase up to an additional 4,153,846 shares of common stock at the offering price, less underwriting discounts and commissions. |
globenewswire.com |
2025-04-23 12:05:00 |
Czytaj oryginał (ang.) |
| Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”) |
Independent Data Monitoring Committee (the “DMC”) recommends continuation of sunRIZE trial as planned with no need to increase sample size Enrollment on track and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. sites activated and enrolling patients REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. |
globenewswire.com |
2025-04-23 12:00:00 |
Czytaj oryginał (ang.) |
| Rezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock? |
Rezolute (RZLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-04-11 17:05:32 |
Czytaj oryginał (ang.) |
| Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors |
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc . (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute. |
globenewswire.com |
2025-03-26 09:30:00 |
Czytaj oryginał (ang.) |
| Rezolute: Late-Stage Study Targeting Hyperinsulinism |
Rezolute is a microcap biopharma focused on developing therapies for hypoglycemia caused by hyperinsulinism, with promising late-stage trials for RZ358 and RZ402. RZ358 targets Congenital Hyperinsulinism and Tumor Hyperinsulinism, showing significant efficacy in reducing hypoglycemia in phase 2 trials. Financially, RZLT has a market cap of $279mn, $105mn in cash, and a cash runway of 5–7 quarters, with manageable expenses. |
seekingalpha.com |
2025-02-18 03:30:44 |
Czytaj oryginał (ang.) |
| Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update |
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and Orphan Drug Designation |
globenewswire.com |
2025-02-12 18:05:00 |
Czytaj oryginał (ang.) |
| RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally? |
Rezolute rides on robust clinical development activity for lead candidate ersodetug (RZ358) for treating hypoglycemia caused by hyperinsulinism. |
zacks.com |
2025-02-06 13:36:09 |
Czytaj oryginał (ang.) |
| Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism |
Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were safely reached at tested doses |
globenewswire.com |
2025-02-04 10:00:00 |
Czytaj oryginał (ang.) |
| Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference |
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that management will participate in the Guggenheim SMID Cap Biotech Conference, taking place February 5-6, 2025, in New York City. |
globenewswire.com |
2025-01-31 10:00:00 |
Czytaj oryginał (ang.) |
| Here's Why 'Trend' Investors Would Love Betting on Rezolute (RZLT) |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Rezolute (RZLT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2025-01-07 11:52:05 |
Czytaj oryginał (ang.) |
| 3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying |
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025. |
zacks.com |
2024-12-24 10:50:25 |
Czytaj oryginał (ang.) |
| Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) |
REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that its compensation committee has approved the issuance of One Hundred and Fifty Thousand (150,000) shares of its common stock as an inducement award (the “Inducement Award”) permitted under Nasdaq Rule 5635(c)(4) to its new Senior Vice President of Global Product Supply. The Inducement Award was granted on November 30, 2024 and was priced at our closing price on November 29, 2024. The Inducement Award will vest 25% one year after the executive's start date and will vest monthly for 36 months after. |
globenewswire.com |
2024-12-05 10:00:00 |
Czytaj oryginał (ang.) |
| RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug |
The FDA bestows an Orphan Drug status to Rezolute's ersodetug for treating hypoglycemia due to tumor hyperinsulinism. Shares rise. |
zacks.com |
2024-12-04 12:56:18 |
Czytaj oryginał (ang.) |
| Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market |
Rezolute, Inc. expects to report top-line results from the phase 3 sunRIZE study using ersodetug + placebo to treat patients with Congenital Hyperinsulinism in the 2nd half of 2025. The global Congenital Hyperinsulinism treatment market is estimated to be worth $327.8 million by 2032; the Company believes that cHI and tHI could both generate sales >$1 billion. A phase 3 registrational study, using ersodetug for patients with Tumor Hyperinsulinism expected to start in the 1st half of 2025 and release top-line data from it 2nd half of 2026. |
seekingalpha.com |
2024-12-03 17:56:36 |
Czytaj oryginał (ang.) |
| Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update |
FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S. |
globenewswire.com |
2024-09-19 20:05:00 |
Czytaj oryginał (ang.) |
| RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study |
The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism. |
zacks.com |
2024-09-10 15:45:19 |
Czytaj oryginał (ang.) |
| FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment |
Monday, the FDA removed partial clinical holds on Rezolute, Inc.'s RZLT RZ358 (ersodetug), a potential treatment for hypoglycemia (low blood sugar) caused by congenital hyperinsulinism (HI). |
benzinga.com |
2024-09-09 14:41:59 |
Czytaj oryginał (ang.) |
| US FDA lifts partial clinical hold on Rezolute's blood sugar treatment |
Rezolute Inc said on Monday the U.S. Food and Drug Administration has removed the partial clinical hold on its late-stage study testing its experimental treatment for low blood sugar. |
reuters.com |
2024-09-09 11:47:20 |
Czytaj oryginał (ang.) |
| FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study |
Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025 Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025 |
globenewswire.com |
2024-09-09 11:30:00 |
Czytaj oryginał (ang.) |
| Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism |
Second rare disease program with RZ358 in Phase 3 development Follows successful treatment of multiple patients with tumor hyperinsulinism under the Company's Expanded Access Program REDWOOD CITY, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that it received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for RZ358 (ersodetug) to treat hypoglycemia in patients with tumor hyperinsulinism (HI). |
globenewswire.com |
2024-08-05 11:30:00 |
Czytaj oryginał (ang.) |
| Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement |
Additional $6.7M in funding resulting in approximately $67M in gross proceeds Additional $6.7M in funding resulting in approximately $67M in gross proceeds |
globenewswire.com |
2024-06-27 12:00:00 |
Czytaj oryginał (ang.) |
| Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds |
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of its underwritten public offering of 11,250,000 shares of its common stock at a price to the public of $4.00 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,750,000 shares of its common stock at a price to the public of $3.999 per pre-funded warrant, in each case, before underwriting discounts and commissions. All of the shares and warrants in the public offering were sold by the Company. |
globenewswire.com |
2024-06-24 12:00:00 |
Czytaj oryginał (ang.) |
| Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants |
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of its previously announced underwritten public offering of an aggregate of 11,250,000 shares of its common stock at an offering price of $4.00 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,750,000 shares of common stock at an offering price of $3.999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and other offering expenses are expected to be approximately $60 million. |
globenewswire.com |
2024-06-14 03:30:00 |
Czytaj oryginał (ang.) |
| Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants |
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof). In addition, the Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of its common stock plus the shares of common stock underlying pre-funded warrants sold in connection with the public offering. The public offering is subject to market and other conditions, and there can be no assurance as to whether or when the public offering may be completed or as to the actual size or terms of the public offering. All of the shares in the public offering are being offered by the Company. |
globenewswire.com |
2024-06-13 20:01:00 |
Czytaj oryginał (ang.) |
| Rezolute to Participate in the Jefferies Global Healthcare Conference |
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute, will participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:00 p.m. ET in New York City. |
globenewswire.com |
2024-05-30 12:00:00 |
Czytaj oryginał (ang.) |
| Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) |
Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention Virtual investor event to be held today at 5:30pm ET REDWOOD CITY, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced positive topline results from the Phase 2 clinical study of RZ402 in patients with DME who are naïve to or have received limited anti-vascular growth factor (anti-VEGF) injections. |
globenewswire.com |
2024-05-21 20:05:00 |
Czytaj oryginał (ang.) |
| $DED: What Do We Know So Far? |
The last few months have seen the Polkadot network come back to life, and ironically, a project called “Dot is Ded” is behind that. Backed by the $DED token, this grassroots memecoin has gone out of its way to get noticed, winning praise and admiration for the way it has leveraged the resilient and never-say-never attitude of the Polkadot community. It’s safe to say that Polkadot is back. Daily trading volume in the past has tipped over $1bn. The community sentiment is absolutely bullish. While the coin price is nowhere near the ATH of the last bull run, optimists and maximalists will argue that there’s nothing stopping them from revisiting a similar price level. Dot is Ded set out with a mission of revitalizing and resurging the Polkadot ecosystem, and while they won’t claim sole responsibility for the recent results, they can be sure that their efforts were a significant catalyst and a bonafide mood changer. They have been helped, in large part, by a mouthwateringly large marketing spend. Almost no new startup in the crypto space has ever had $1m to work with. $DED is built different. With no celebrity backers, no VCs, and just a community team and mission, they had to get creative. This is what DAOs, governance, and treasuries were built for, and so, instead of selling equity for funds, $DED went to Polkassembly and simply asked for some DOT. Here’s the opening statement of their pitch: “Market sentiment is shifting, and several treasuries are actively investing to stimulate growth and excitement during this bull run. For example, Solana’s initiatives, such as $BONK, are leveraging this opportunity effectively. This project’s funding rationale is to capitalize on the memecoin trend as a marketing tool for the DOT ecosystem and to showcase Polkadot’s diversity and buzz-generating capabilities.” It worked. On December 27th, 2023, Polkadot’s DAO voted 61% in favour of releasing 91,557 DOT to the $DED team. At the time, the value was around $8.41 per DOT, but since then the price performed well, peaking at around $10.75. Therefore, the total value of their 91,557 peaked at about $975,000, just shy of $1m. Lunar Strategy, Flight3, and RZLT, the three marketing agencies behind the pitch and now leading an exciting multi-pronged marketing campaign, can revel in the fact that their previous work had already positioned $DED as the leading DOT memecoin. This was crucial to them being selected to bring Polkadot back to life. DOT is DED ($DED), the community-centric memecoin revitalizing the Polkadot ($DOT) network, has listed on the top-10 cryptocurrency exchange MEXC. Users committed 49,939,063 $MX to support the DED listing during MEXC’s Kickstarter campaign. These campaigns help identify high-quality projects and offer free airdrops to users. This centralized exchange listing enhances the legitimacy of DOT is DED, which has already received over $1m from the DOT treasury and distributed $DED to over 1.3m DOT wallet holders via a free airdrop. The $DED listing now exposes it to more than 10 million MEXC customers in 170 countries. MEXC benefits from the active DED community and the fact that many DED holders are also Polkadot supporters. The DED/USDT trading pair opened on MEXC on May 9th at 11:00 (UTC) and saw over $1.7m in trades within the first four days, with the highest volume of $527,800 on May 11th. MEXC, ranking between 10th and 11th in trading volumes with over 2,100 cryptocurrencies, offers $DED a larger ecosystem, aiming to boost trading volumes and engagement. This partnership is crucial for DED’s longevity and success, promoting activity on the Polkadot network. Dot is Ded has been talked about by some of the biggest influencers in the crypto space recently. Take Lark Davis for example, with over 1.1m followers, who shared a tweet of him unstaking his $DOT to make sure it qualifies for the $DED airdrop. This same activity was then shared by AshCrypto to his 1m followers, this time showing exactly how much $DOT he was moving – about $2m worth. That Martini Guy, with 540k followers, told his huge audience exactly how to qualify for the airdrop, with Boxmining (211k) saying “$DED will be THE meme coin on $DOT”. Mando CT (207k) tweeted “I just bought over 3000 $DOT (21,300 USD) from KuCoin and transferred to my wallet to join the $DED Airdrop on Polkadot.”, before shouting out Subwallet, Talisman, and Nova, in another display of ecosystem support. Finally, YouTubers DataDash, DubzyXBT, and CyrilXBT have all also made positive comments about $DED in recent videos. Partnerships, collaborations, grassroots activities – call them what you like, but a common theme that has inspired not just the Polkadot network, but other blockchains too, is how DED has driven people to take action. The community has banded together in style. One poignant example of community involvement is from the Astar Network, which has granted $DED token holders full access to their new game, Astar Strike. They’re also going to redistribute any $DED they get from the airdrop to their own NFT holders – talk about layers! Polkadot wallets and bridges have also gotten involved, in a major way. StellaSwap, a hybrid DEX on Moonbeam, introduced a new DED-DOT feature where users could stake DOT and still qualify for the airdrop. Bitfrost then did the same, building a similar liquid staking feature. Neurolanch and Talisman are running a 350 DOT (~$2800) giveaway in the build-up to $DED’s release, Nova Wallet is giving 20 people 20 DOT each, and Subwallet App is giving 20 people 10 DOT each. The $DED project has breathed new life into the Polkadot network, leveraging community support and strategic marketing to achieve significant milestones. From securing a $1m marketing budget through Polkadot’s DAO to listing on major exchanges like MEXC, Hydradx, and Stellaswap, $DED has proven its impact. Influencer endorsements and strong community partnerships further underscore its success. As $DED continues to stimulate activity within the Polkadot ecosystem, its journey showcases the power of grassroots efforts in the crypto space. |
https://finbold.com |
2024-05-20 15:28:26 |
Czytaj oryginał (ang.) |
| Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update |
Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 |
globenewswire.com |
2024-05-15 20:05:00 |
Czytaj oryginał (ang.) |
| Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting |
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study” will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk. |
globenewswire.com |
2024-04-23 12:00:00 |
Czytaj oryginał (ang.) |
| Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024? |
Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio. |
investorplace.com |
2024-04-15 19:43:32 |
Czytaj oryginał (ang.) |